(89 days)
Not Found
No
The device description and performance studies focus on mechanical and material properties, with no mention of AI/ML capabilities or data processing.
No.
The device is a surgical tool used to divide ligaments or fascia; it does not directly treat or prevent a disease, but rather performs a surgical function.
No
The HBL Blade Assembly is a surgical device used for cutting ligaments or fascia during endoscopic procedures, not for diagnosing conditions.
No
The device description clearly states it is a surgical device composed of physical components like plastic, a spring, and a cutting blade, and is provided sterile for single use. It is not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "minimally invasive ligament or fascia release" during surgical procedures (carpal tunnel release and cubital tunnel release). This is a surgical intervention, not a diagnostic test performed on samples taken from the body.
- Device Description: The device is a surgical tool designed to cut tissue (ligament or fascia) within the body. It is not designed to analyze biological samples (blood, urine, tissue, etc.) to provide diagnostic information.
- Lack of Diagnostic Elements: There is no mention of analyzing samples, detecting biomarkers, or providing any form of diagnostic information about a patient's condition.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device is a surgical instrument used for treatment.
N/A
Intended Use / Indications for Use
The HBL Blade Assembly is indicated for use with the 3M Agee Inside Job Carpal Tunnel Release System or MicroAire SmartRelease Endoscopic Soft Tissue Release System in minimally invasive ligament or fascia release:
- Carpal tunnel release in the wrist
- Cubital tunnel in the elbow
Product codes
HRX
Device Description
The HBL Blade Assembly is a surgical device designed to divide the ligament during an endoscopic carpal tunnel release (ECTR) or the fascia during an endoscopic cubital tunnel release (ECuTR). This device is capable of elevating a cutting blade from a retracted position within the cannula to an exposed position for cutting the ligament or fascia. Once the ligament or fascia has been divided, the cutting blade can be returned to a safe position within the cannula.
The HBL Blade Assembly is composed of a probe assembly that is fabricated using medical grade injection molded plastic, and both a spring and cutting blade that are fabricated using stainless steel. The Blade Assembly is provided sterile and designed for single use.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
wrist, elbow
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Study type: Blade Activation Mechanism Performance; Sample size: Not Specified; Key results: A cyclic load test verified the device is capable of exceeding typical surgical requirements without any failure or malfunction.
Study type: Cutting Blade Comparison; Sample size: Not Specified; Key results: A comparison of the cutting performance was performed using both devices.
Study type: Static Overload Performance; Sample size: Not Specified; Key results: The device coupled with the predicate system were tested to ensure the device could withstand the forces that may be applied to the handpiece trigger.
Study type: Bending Stiffness Comparison; Sample size: Not Specified; Key results: A comparison of device stiffness was performed using both devices.
Study type: Cadaveric Study; Sample size: Multiple surgeons; Key results: Study participants demonstrated the subject device can perform its intended use safely and effectively per the instructions for use.
All test results demonstrated the HBL Blade Assembly performs the intended use safely and effectively.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.1100 Arthroscope.
(a)
Identification. An arthroscope is an electrically powered endoscope intended to make visible the interior of a joint. The arthroscope and accessories also is intended to perform surgery within a joint.(b)
Classification. (1) Class II (performance standards).(2) Class I for the following manual arthroscopic instruments: cannulas, currettes, drill guides, forceps, gouges, graspers, knives, obturators, osteotomes, probes, punches, rasps, retractors, rongeurs, suture passers, suture knotpushers, suture punches, switching rods, and trocars. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 888.9.
0
November 14, 2022
Image /page/0/Picture/1 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left side of the logo is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
Hand Biomechanics Lab, Inc Dustin Dequine CFO 77 Scripps Drive, Suite 104 Sacramento, California 95825
Re: K222490
Trade/Device Name: HBL Blade Assembly Regulation Number: 21 CFR 888.1100 Regulation Name: Arthroscope Regulatory Class: Class II Product Code: HRX Dated: August 17, 2022 Received: August 17, 2022
Dear Dustin Dequine:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Sara S. Thompson -S
For
Laura C. Rose, Ph.D. Assistant Director DHT6C: Division of Restorative, Repair, and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K22490
Device Name HBL Blade Assembly
Indications for Use (Describe)
The HBL Blade Assembly is indicated for use with the 3M Agee Inside Job Carpal Tunnel Release System or MicroAire SmartRelease Endoscopic Soft Tissue Release System in minimally invasive ligament or fascia release:
-
Carpal tunnel release in the wrist
-
Cubital tunnel in the elbow
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------ |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/1 description: The image shows the logo for the Hand Biomechanics Lab. The logo features a stylized hand in purple, with a gray arc above it. To the right of the hand is the text "Hand Biomechanics Lab", with each word on a separate line. The text is also in purple.
510(k) Summary
| Owner Information: | Hand Biomechanics Lab, Inc.
77 Scripps Drive, Suite 104
Sacramento, CA 95825-6209
Telephone: (916) 923-5073
Facsimile: (916) 920-2215
Contact Person: Dustin Dequine
Email: ddequine@handbiolab.com |
| -------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
|---|
Date Prepared: November 14, 2022
Name of Device: Trade Name: HBL Blade Assembly Model Number: CTR-455 Common Name: Blade Assembly Classification Name: Arthroscope [21CFR 888.1100, Product Code: HRX] Classification: Class II
Predicate Device: MicroAire® SmartRelease® Endoscopic Soft Tissue Release System, K181819
Description of Device:
The HBL Blade Assembly is a surgical device designed to divide the ligament during an endoscopic carpal tunnel release (ECTR) or the fascia during an endoscopic cubital tunnel release (ECuTR). This device is capable of elevating a cutting blade from a retracted position within the cannula to an exposed position for cutting the ligament or fascia. Once the ligament or fascia has been divided, the cutting blade can be returned to a safe position within the cannula.
The HBL Blade Assembly is composed of a probe assembly that is fabricated using medical grade injection molded plastic, and both a spring and cutting blade that are fabricated using stainless steel. The Blade Assembly is provided sterile and designed for single use.
Indications for Use:
The HBL Blade Assembly is indicated for use with the 3M Agee Inside Job Carpal Tunnel Release System or MicroAire SmartRelease Endoscopic Soft Tissue Release System in minimally invasive ligament or fascia release:
- Carpal tunnel release in the wrist
- Cubital tunnel in the elbow
Technological Characteristics Compared to Predicate Device:
The HBL Blade Assembly is comparable to the blade assembly of the predicate device with respect to technology, materials, and design. Both are indicated for minimally invasive ligament release of the carpal tunnel in the wrist and fascia release of the cubital tunnel in the elbow. Both use a blade activation mechanism with a spring to elevate and retract the cutting blade.
There are also minor design differences between the proposed and predicate devices. Specifically, the predicate uses a wireform but the proposed device does not. The purpose of the wireform in the predicate device is to ensure the blade retraction path is predominantly vertical. In the subject device, the curvature of the blade slot has the same effect by controlling the location of the blade. Both blade retraction methods accomplish the same predominantly vertical path and have the same functional purpose.
Both devices are made of plastic and metal components. The exact polymer and color additive, if any, is unknown for the predicate device; however, the safety and effectiveness of the proposed device materials have been demonstrated through the performance testing. Both are delivered to the customer sterile.
4
Performance Data:
The following performance data were provided in support of the substantial equivalence determination.
Blade Activation Mechanism Performance:
Both the predicate and subject devices are anticipated to be cycled during a typical surgical procedure. A cyclic load test verified the device is capable of exceeding typical surgical requirements without any failure or malfunction.
Cutting Blade Comparison:
Both the predicate and subject devices utilize a cutting blade to divide the ligament or fascia. A comparison of the cutting performance was performed using both devices.
Static Overload Performance:
Both the predicate and subject devices transfer load from the handpiece trigger to the blade through a pushrod. The device coupled with the predicate system were tested to ensure the device could withstand the forces that may be applied to the handpiece trigger.
Bending Stiffness Comparison:
Both the predicate and subject devices experience a bending load to the palmar surface of the blade assembly probe as the surgeon lifts the blade assembly aqainst the deep surface of the ligament or fascia. A comparison of device stiffness was performed using both devices.
Sterilization, Packaqing & Shelf Life:
The subject device is supplied sterile and is a single use device. The subject device is sterilized via gamma irradiation. The sterilization cycle has been validated to a sterility assurance level (SAL) of 10-6, in accordance with AAMI TIR 13004:2013 (R2016) Sterilization of Healthcare Products - Radiation - Substantiation of a selected dose: Method VDmaxSD.
The subject device sterile packaging was validated in accordance with the following standards as part of a study demonstrating that the packaging system is stable over its labeled shelf life:
- . ISO 11607-1:2019, Packaging for terminally sterilized medical devices - Part 1: Requirements for materials, sterile barrier systems and packaging systems
- ASTM F1929-15, Standard Test Method for Detecting Seal Leaks in Porous Medical Packaging by Dye Penetration
- ASTM F88/F88M-15, Standard Test Method for Seal Strength of Flexible Barrier ● Materials
- ASTM F1886/F1886M-16, Standard Test Method for Determining Integrity of Seals ● for Flexible Packaging by Visual Inspection
Biocompatibility:
In accordance with ANSI/AAMI/ISO 10993-1:2018, the subject device is classified as "external communicating device", in contact with "tissue/bone/dentin" and "limited exposure" (≤ 24 hours).
Cadaveric Study:
Multiple surqeons with experience using the predicate device participated in a cadaveric study to evaluate the subject device. Study participants demonstrated the subject device can perform its intended use safely and effectively per the instructions for use.
Summary
The predicate and subject devices operate under similar technological and functional principles using similar materials. Device functional tests and a cadaveric study by multiple surgeons were
5
performed to evaluate the subject device for compatibility with the predicate system. All test results demonstrated the HBL Blade Assembly performs the intended use safely and effectively.